Journal of Hepatology
Volume 52, Issue 3 , Pages 322-329 , March 2010

T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B

  • Ying Ju

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • Shandong Provincial Hospital Affiliated to Shandong University, #324 Jingwu Weiqi Road, Jinan, Shandong 250021, PR China
    • These authors contributed equally to this work.
    • ,
  • Nan Hou

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • These authors contributed equally to this work.
    • ,
  • Jing Meng

      Affiliations

    • The Second Affiliated Hospital of Shandong University, #247 Beiyuan Road, Jinan, Shandong 250033, PR China
    • ,
  • Xiaoyan Wang

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Xiaoning Zhang

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Di Zhao

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Ying Liu

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Faliang Zhu

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Lining Zhang

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Wensheng Sun

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Xiaohong Liang

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Lifen Gao

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • ,
  • Chunhong Ma

      Affiliations

    • Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Shandong University, Qilu Hospital, #107 Wenhua Xi Road, Jinan, Shandong 250012, PR China
    • Corresponding Author InformationCorresponding author. Address: Institute of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong University School of Medicine, 44# Wenhua Xi Road, Jinan, Shandong 250012, PR China. Tel.: +86 531 88382038; fax: +86 531 88382502.

Received 24 February 2009 ,Revised 30 August 2009 ,Accepted 9 September 2009.

References 

  1. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis. 2002;2:43–50
  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  3. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000
  4. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997;9:24–34
  5. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000;192:921–930
  6. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol. 2002;169:5188–5195
  7. Pasquetto V, Guidotti LG, Kakimi K, Tsuji M, Chisari FV. Host-virus interaction during malaria infection in hepatitis B virus transgenic mice. J Exp Med. 2000;192:529–535
  8. Echevarria S, Casafont F, Miera M, Lozano JL, de la Cruz F, San Miguel G, et al. Interleukin-2 and natural killer activity in acute type B hepatitis. Hepatogastroenterology. 1991;38:307–310
  9. Monsalve-De Castillo F, Romero TA, Estévez J, Costa LL, Atencio R, Porto L, et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol. 2002;9:1372–1375
  10. Ono K, Yamanaga Y, Yamamoto K, Koga SI, Nishimura J, Nawata H. Natural killing activities in chronic liver diseases and hepatocellular carcinoma. J Clin Immunol. 1996;16:41–45
  11. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–541
  12. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102–1110
  13. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093–1101
  14. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–1252
  15. Khademi M, Illés Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, et al. T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 2004;172:7169–7176
  16. Koguchi K, Anderson DE, Yang L, O’Connor KC, Kuchroo VK, Hafler DA. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203:1413–1418
  17. Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, et al. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol. 2008;67:63–70
  18. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141–1143
  19. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJ, Njoku DB, et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411–6415
  20. Oikawa T, Kamimura Y, Akiba H, Yagita H, Okumura K, Takahashi H, et al. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol. 2006;177:4281–4287
  21. Kearley J, McMillan SJ, Lloyd CM. Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo. J Exp Med. 2007;204:1289–1294
  22. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710–6714
  23. Zhang J, Gu Y, Xu C, Qu X. Increased T cell immunoglobulin mucin-3 and its ligand in acquired aplastic anemia. Eur J Haematol. 2008;81:130–139
  24. Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets. 2007;11:1005–1009
  25. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127:78–88
  26. Yang L, Anderson DE, Kuchroo J, Hafler DA. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008;180:4409–4414
  27. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763–2779
  28. Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009;6:35–43
  29. Wang F, Wan L, Zhang C, Zheng X, Li J, Chen ZK. Tim-3-galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology. 2009;214:342–349
  30. Zhao J, Lei Z, Liu Y, Li B, Zhang L, Fang H, et al. Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol. 2009;182:6618–66124
  31. St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2008;24:327–328
  32. Mary AS, Meiling C, Georage A. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 1987;84:1005–1009
  33. Xiong Y, Jia Y, Wang H, Liu G, Zhang Y. High-level hepatitis B virus expression in transgenic mice. Infect Dis Info. 2000;13:164–165
  34. Dong Z, Zhang J, Sun R, Wei H, Tian Z. Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice. Hepatology. 2007;45:1400–1412
  35. Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma C, et al. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol. 2007;178:503–510
  36. Grund EM, Muise-Helmericks RC. Cost efficient and effective gene transfer into the human natural killer cell line, NK92. J Immunol Methods. 2005;296:31–36
  37. Kekulé AS, Lauer U, Weiss L, Hofschneider PH, Koshy R. Trans-activation by hepatitis B virus X protein is mediated via a tumour promoter pathway. Arch Virol Suppl. 1992;4:63–64
  38. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004;18:1123–1125
  39. Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev. 2001;15:455–466
  40. Chang JJ, Thompson AJ, Visvanathan K, Kent SJ, Cameron PU, Wightman F, et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology. 2007;46:1332–1340

PII: S0168-8278(09)00806-X

doi: 10.1016/j.jhep.2009.12.005

Journal of Hepatology
Volume 52, Issue 3 , Pages 322-329 , March 2010

Article Tools

* Image Usage & Resolution